(Q57117791)

English

Breast cancer

scientific article published on 17 November 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27865536%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

1 reference

Europe PubMed Central

Breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27865536%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

author name string

Nadia Harbeck

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27865536%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Michael Gnant

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27865536%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

language of work or name

0 references

publication date

17 November 2016

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27865536%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

number of pages

17

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27865536%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

389

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27865536%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

10074

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27865536%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

1134-1150

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27865536%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Global cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

European cancer mortality predictions for the year 2016 with focus on leukaemias

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative magnetic resonance imaging in breast cancer: meta-analysis of surgical outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Perioperative screening for metastatic disease is not indicated in patients with primary breast cancer and no clinical signs of tumor spread.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Personalized treatment of early-stage breast cancer: present concepts and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

An international Ki67 reproducibility study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Surgical management of the breast: breast conservation therapy and mastectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Variations in compliance to quality indicators by age for 41,871 breast cancer patients across Europe: a European Society of Breast Cancer Specialists database analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Surgical margins in lumpectomy for breast cancer--bigger is not better

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The value of intraoperative frozen section analysis for margin status in breast conservation surgery in a nontertiary institution

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of analysis of frozen-section margin on reoperation rates in women undergoing lumpectomy for breast cancer: evaluation of the National Surgical Quality Improvement Program data.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A systematic review of oncoplastic breast-conserving surgery: current weaknesses and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998-2002.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Postmastectomy radiotherapy in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy in early breast cancer: when, how and which one?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant therapy in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant as Future for Drug Development in Breast Cancer--Response.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Surgical treatment of primary breast cancer in the neoadjuvant setting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Surgical Considerations After Neoadjuvant Chemotherapy: Breast Conservation Therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus gui

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative breast MRI for early-stage breast cancer: effect on surgical and long-term outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative MRI of the breast (POMB) influences primary treatment in breast cancer: a prospective, randomized, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Local treatment of the axilla in early breast cancer: concepts from the national surgical adjuvant breast and bowel project B-04 to the planned intergroup sentinel mamma trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis of superficial versus deep injection of radioactive tracer and blue dye for lymphatic mapping and detection of sentinel lymph nodes in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Patterns of Local-Regional Management Following Neoadjuvant Chemotherapy in Breast Cancer: Results From ACOSOG Z1071 (Alliance).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (All

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiation field design in the ACOSOG Z0011 (Alliance) Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The evolving role of partial breast irradiation in early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results of hypofractionated radiation therapy for breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Accelerated partial irradiation for breast cancer: systematic review and meta-analysis of 8653 women in eight randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Boost IORT in Breast Cancer: Body of Evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Intraoperative Electron Radiotherapy (IOERT) as an Alternative to Standard Whole Breast Irradiation: Only for Low-Risk Subgroups?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Breast-conserving surgery with or without radiotherapy in older breast patients with early stage breast cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Lumpectomy Plus Tamoxifen or Anastrozole With or Without Whole Breast Irradiation in Women With Favorable Early Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Regional Nodal Irradiation in Early-Stage Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant radiation therapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials- an update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Contemporary Breast Radiotherapy and Cardiac Toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population-based study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor Bed Boost Integration during Whole Breast Radiotherapy: A Review of the Current Evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A gene-expression signature as a predictor of survival in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant ovarian suppression in premenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: current and future evidence.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Late recurrences in early breast cancer: for whom and how long is endocrine therapy beneficial?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo (GONO-MIG) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of occult metastases on survival in node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Time to begin adjuvant chemotherapy and survival in breast cancer patients: a retrospective observational study using latent class analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant chemotherapy in older women with early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant trastuzumab in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a r

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of bisphosphonates in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone health in cancer patients: ESMO Clinical Practice Guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of bone-targeted agents on cancer progression and mortality.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Breast-cancer adjuvant therapy with zoledronic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

First international consensus guidelines for breast cancer in young women (BCY1).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Fertility Preservation Methods in Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of breast cancer during pregnancy: an observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The treatment of early breast cancer in women over the age of 70

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab emtansine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiogenesis inhibitors in the management of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The AURORA initiative for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931891-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(16)31891-8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27865536%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27865536%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57117791&oldid=1770267872"